Bristol-Myers Cancer Combo Has Tepid Result Against Chemotherapy

Bristol-Myers Squibb Co.’s blockbuster oncology drug showed tepid results in a trial of lung-cancer patients, in what investors may read as a setback in the competitive market drugs that unleash the immune system to attack tumors.

The trial compared chemotherapy treatment against a cocktail of Bristol-Myers’s Opdivo and a low dose of its drug Yervoy. Patients who got the new, expensive drugs lived an average of 17.1 months, compared with 14.9 months on chemotherapy.